TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

XADAGO

SAFINAMIDE MESYLATE
Neurology Approved 2017-03-21
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2017-03-21
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: SAFINAMIDE MESYLATE

XADAGO Approval History

Loading approval history...

What XADAGO Treats

1 indications

XADAGO is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Parkinson's Disease
Source: FDA Label

Drugs Similar to XADAGO

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AZILECT
RASAGILINE MESYLATE
1 shared
Teva
Shared indications:
Parkinson's Disease
COMTAN
ENTACAPONE
1 shared
ORION PHARMA
Shared indications:
Parkinson's Disease
CREXONT
CARBIDOPA
1 shared
IMPAX
Shared indications:
Parkinson's Disease
DHIVY
CARBIDOPA
1 shared
AVION PHARMS
Shared indications:
Parkinson's Disease
DROXIDOPA
DROXIDOPA
1 shared
Aurobindo Pharma
Shared indications:
Parkinson's Disease
DUOPA
CARBIDOPA
1 shared
AbbVie
Shared indications:
Parkinson's Disease
GOCOVRI
AMANTADINE HYDROCHLORIDE
1 shared
SUPERNUS PHARMS
Shared indications:
Parkinson's Disease
INBRIJA
LEVODOPA
1 shared
MERZ
Shared indications:
Parkinson's Disease
LODOSYN
CARBIDOPA
1 shared
ATON
Shared indications:
Parkinson's Disease
NEUPRO
ROTIGOTINE
1 shared
UCB INC
Shared indications:
Parkinson's Disease
NORTHERA
DROXIDOPA
1 shared
LUNDBECK NA LTD
Shared indications:
Parkinson's Disease
NOURIANZ
ISTRADEFYLLINE
1 shared
KYOWA KIRIN
Shared indications:
Parkinson's Disease
ONAPGO
APOMORPHINE HYDROCHLORIDE
1 shared
MDD US
Shared indications:
Parkinson's Disease
ONGENTYS
OPICAPONE
1 shared
AMNEAL
Shared indications:
Parkinson's Disease
PARLODEL
BROMOCRIPTINE MESYLATE
1 shared
ESJAY PHARMA
Shared indications:
Parkinson's Disease
RASAGILINE MESYLATE
RASAGILINE MESYLATE
1 shared
ORBION PHARMS
Shared indications:
Parkinson's Disease
RYTARY
CARBIDOPA
1 shared
IMPAX
Shared indications:
Parkinson's Disease
SAFINAMIDE MESYLATE
SAFINAMIDE MESYLATE
1 shared
PRINSTON INC
Shared indications:
Parkinson's Disease
SINEMET
CARBIDOPA
1 shared
Merck
Shared indications:
Parkinson's Disease
STALEVO 100
CARBIDOPA
1 shared
ORION PHARMA
Shared indications:
Parkinson's Disease
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XADAGO FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes

XADAGO Patents & Exclusivity

Latest Patent: Mar 2031

Patents (12 active)

US8283380 Expires Mar 21, 2031
US8076515 Expires Dec 10, 2028
US8278485 Expires Jun 8, 2027
+ 2 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.